Fannie Mae, Freddie Mac shares tumble after conservatorship comments
WILMINGTON, Del. - DuPont (NYSE:DD), a $28.4 billion market cap company with annual revenues exceeding $12.5 billion, has announced the release of a new agarose-based chromatography resin, branded as DuPont™ AmberChrom™ TQ1, designed to enhance the purification process of oligonucleotides and peptides used in biopharmaceutical applications. According to InvestingPro analysis, the company is currently trading below its Fair Value, presenting a potential opportunity for investors interested in established dividend-paying stocks.
The company stated that the AmberChrom™ TQ1 resin offers improved performance features, including increased loading capacity and higher throughput, while operating under lower pressure compared to similar products. These advancements are expected to provide more efficient high-resolution separations and polishing stages in the purification of biomolecules. With a robust financial health score rated as "GOOD" by InvestingPro, DuPont continues to demonstrate strong operational capabilities while maintaining its 55-year streak of consistent dividend payments.
According to DuPont, the resin is particularly adept at separating closely-related impurities from target molecules, delivering high-purity results. The product is suitable for a range of applications, from benchtop experiments to large-scale commercial purifications.
Shane Kendra, Global Bioprocessing Market Leader for DuPont Water Solutions, remarked on the significance of the new product, emphasizing its role in accelerating the development and commercialization of therapeutic oligonucleotides and peptides. He also noted the company’s commitment to offering comprehensive solutions for the bioprocessing industry.
To validate the performance of the AmberChrom™ TQ1 resin, DuPont conducted internal application studies using real-world drug feeds. These studies are intended to assist clients in integrating the new resin into their drug development processes.
The resin complements DuPont’s existing bioprocessing portfolio, which includes other AmberChrom™ resins, and can be used in various purification workflows. DuPont introduced the product at TIDES USA, a conference focused on oligonucleotide and peptide innovation, where application studies were presented.
Looking ahead, DuPont plans to host an educational webinar on June 19, 2025, to further discuss the capabilities of the AmberChrom™ TQ1 resin and its potential impact on the purification of oligonucleotides and peptides.
This announcement is based on a press release statement from DuPont, a global leader in technology-based materials and solutions. The company is listed on the New York Stock Exchange under the ticker NYSE:DD.
In other recent news, DuPont reported its first-quarter earnings for 2025, surpassing analysts’ expectations with an EPS of $1.03, compared to the forecasted $0.96. The company’s revenue also exceeded projections, reaching $3.07 billion against an anticipated $3.05 billion. In addition, DuPont announced the spin-off of its Electronics business, which will be branded as Qnity, aiming for completion by November 1, 2025. BMO Capital Markets adjusted their valuation of DuPont shares, reducing the price target from $116 to $100, while maintaining an Outperform rating, citing strong fundamentals and the upcoming company split as key factors. Meanwhile, Citi analysts increased their price target on DuPont shares to $75 from $74, maintaining a Buy rating, following discussions about DuPont’s financial strategies and market outlook. In another development, DuPont has partnered with Epicore Biosystems to integrate wearable technology with protective clothing to enhance worker safety. These recent developments reflect DuPont’s strategic initiatives to strengthen its market position and focus on innovation across various sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.